The Difference Between 503b and 506e FDA Outsourcing Drug Compounding Facilities-MayMag Biologics
Regulatory and Operational Comparison Matrix While both model types alleviate drug availability issues, Section 506E Drug Shortage Manufacturers and Section 503B Outsourcing Facilities operate under fundamentally distinct statutory provisions, target different distribution channels, and follow different regulatory requirements under the Federal Food, Drug, and Cosmetic (FD&C) Act. Feature / Dimension 506(e) Industrial Shortage Manufacturer 503B Compounding Outsourcing Facility Statutory Authority FD&C Act § 506E (21 U.S.C. § 356e) FD&C Act § 503B (21 U.S.C. § 353b) Primary Scope & Purpose Commercial-scale manufacturing and market replenishment of critical generic drugs & biologics officially designated on the FDA Drug Shortage list. Custom office-stock compounding, small-to-medium batch preparation, and clinical supply for hospitals, clinics, and health systems. Primary Target Market Wholesale healthcare distributors, national GPOs, prime vendors, and f...